Please use this identifier to cite or link to this item:
Title: Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)
Authors: Steingo, Brian
Oreja-Guevara, Celia
Alroughani, Raed
Brassat, David
Boyko, Alexey N.
McCombe, Pamela
Margolin, David H.
Melanson, Maria
Daizadeh, Nadia
Rodriguez, Claudio E.
Vermersch, Patrick
Issue Date: 2018
Source: NEUROLOGY, 90(15) (Art N° P6.376)
Notes: [Steingo, Brian] Ft Lauderdale Multiple Sclerosis Ctr, Ft Lauderdale, FL USA. [Oreja-Guevara, Celia] Univ Hosp San Carlos, Madrid, Spain. [Alroughani, Raed] Amiri Hosp, Sharq, Kuwait. [Brassat, David] Univ Toulouse, Purpan Hosp, Toulouse, France. [Brassat, David] Univ Toulouse, Mixed Unit Res 1043, Toulouse, France. [Boyko, Alexey N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, Alexey N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [McCombe, Pamela] Univ Queensland, Brisbane, Qld, Australia. [Van Wijmeersch, Bart] Hasselt Univ, Rehabil, Hasselt, Belgium. [Van Wijmeersch, Bart] Hasselt Univ, MS Ctr Overpelt, BIOMED, Hasselt, Belgium. [Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.] Sanofi, Cambridge, MA USA. [Vermersch, Patrick] Univ Lille, Lille, France.
Document URI:
ISSN: 0028-3878
e-ISSN: 1526-632X
ISI #: 000453090805102
Rights: 2018, American Academy of Neurology
Category: M
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Schmidtea mediterranea as an alternative model to predict carcinogenicity via its stem cell responses _ Elsevier Enhanced Reader.pdf
  Restricted Access
Published version - Experiment data readings712.7 kBAdobe PDFView/Open    Request a copy
Show full item record

Page view(s)

checked on May 28, 2022


checked on May 28, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.